Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
This award is open to all currently operational laboratories pertaining to testing, calibration & medical including their proficiency testing providers & reference material producers located in India
Subscribe To Our Newsletter & Stay Updated
